文拉法新缓释剂治疗86例广泛性焦虑症的临床对照研究

目的：评价文拉法新缓释剂治疗广泛性焦虑症的临床疗效和不良反应。方法：随机抽取86例广泛性焦虑症患者分为两组，分别服用文拉法新缓释剂或阿普唑仑，疗程8周。于治疗前及治疗后1、2、4、6、8周末进行汉密尔顿焦虑量表（HAMA）及副反应量表（TESS）评定疗效和不良反应。结果：文拉法新缓释剂与阿普唑仑疗效相似，文拉法新缓释剂起效时间比阿普唑仑快，不良反应少而轻，无成瘾性。结论：文拉法新缓释剂是治疗广泛性焦虑症的安全、起效快的药物。

Clinic contrast study of Venlafaxine slow release for treatment of Generalized Anxiety disorder(GAD)

Objective:To assess the clinic efficacy and adverse reaction of Venlafaxine slow release for the treatment of generalized anxiety disorder(GAD).Methods:86 patients with GAD were divided into two groups,and took Venlafaxine and Alprzolam separately in a treatment course for 8 weeks.Assess the efficacy and adverse reaction with HAMA and TESS before treatment and at the end of weeks 1,2,4,6,and 8 after treatment.Results: In contrast with Alprazolam,Venlafaxine has similar effect,fast reaction time,less side effect and no addiction.Conclusions: Venlafaxine slow release is a safe and fast effective medicine for the treatment of GAD.